Pharmafile Logo

OTC Awards

- PMLiVE

Is COVID-19 yet another barrier to contraceptive access?

In this blog, we’re revisiting the concerns raised in our 2020 MAGNIFI around women’s access to contraceptives in the UK and beyond alongside the influence of the COVID-19 pandemic.

IGNIFI

- PMLiVE

Merck to acquire Acceleron in a deal worth around $11.5bn

The acquisition of the biopharmaceutical company will complement and strengthen Merck’s cardiovascular pipeline

Article:

All change – how untangling human behaviour can encourage better health

Inizio

Webcast:

Understanding changing digital behaviours: Insights needed for an effective omnichannel strategy

Inizio

Attracting the best talent to build Lucid’s future

Q: Welcome to Lucid, Jon! Tell us what you love about recruitmentA: I love being able to play my part in shaping a company’s growth story through the hiring of...

Lucid Group Communications Limited

Steven Cohen at BOLDSCIENCE

BOLDSCIENCE welcomes Steven Cohen to its leadership team to expand its strategic communication consulting services into regulatory approvals

Medical communications agency BOLDSCIENCE has hired industry veteran Steven Cohen to lead a new division that will help pharmaceutical and biotech clients navigate the most critical challenges they face throughout...

BOLDSCIENCE

Making Digital Trust and Privacy Accessible to Everyone

Mike Cook, CEO of IDENTOS, shares how his company is making digital trust and privacy accessible for patients, healthcare providers, payers, organizations, and connected devices. He also discusses “smart cities”...

Impetus Digital

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Impetus Digital

- PMLiVE

AZ buys Caelum Biosciences for $500m

After AstraZeneca’s Alexion acquires all remaining equity in Caelum next week it will 'advance and accelerate' ongoing clinical development

- PMLiVE

Positive data for Lyme disease booster vaccine

A booster shot of Valneva/Pfizer’s VLA15 vaccine candidate against tick-borne Lyme disease demonstrates a strong immune response

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links